Table 2.
Demographics and clinical and treatment characteristics for patients with haemophilia A receiving standard half-life vs. extended half-life factor VIII replacement products in the United States and Europe
| The United States, N = 110 | Europe, N = 391 | Combined, N = 501 | ||||
| Characteristic | SHL group, n = 74 | EHL group, n = 36 | SHL group, n = 361 | EHL group, n = 30 | SHL group, n = 435 | EHL group, n = 66 |
| Age, mean (SD) (years) | 27.5 (13.9) | 24.0 (12.2) | 29.9 (15.9) | 27.2 (13.5) | 29.5 (15.6) | 25.5 (12.8) |
| Weight, mean (SD) (kg) | 74.3 (20.5) | 70.9 (19.8) | 68.0 (15.0) | 65.4 (12.2) | 68.0 (15.0) | 65.4 (12.2) |
| BMI, mean (SD) (kg/m2) | 25.0 (5.0) | 24.3 (4.1) | 23.4 (3.3) | 22.4 (2.9) | 23.7 (3.7) | 23.5 (3.7) |
| Race/ethnicity, n (%)a | ||||||
| White | 54 (73.0) | 31 (86.1) | 337 (93.4) | 27 (90.0) | 391 (89.9) | 58 (87.9) |
| Black/African American | 11 (14.9) | 3 (8.3) | 0 | 0 | 11 (2.5) | 3 (4.5) |
| Hispanic/Latino | 4 (5.4) | 1 (2.8) | 2 (0.6) | 1 (3.3) | 6 (1.4) | 2 (3.0) |
| Otherb | 5 (6.8) | 1 (2.8) | 22 (6.1) | 2 (6.7) | 27 (6.2) | 3 (4.5) |
| Haemophilia severity, n (%) | ||||||
| Moderate | 50 (68) | 18 (50) | 180 (50) | 21 (70) | 230 (53) | 39 (59) |
| Severe | 24 (32) | 18 (50) | 181 (50) | 9 (30) | 205 (47) | 27 (41) |
| Inhibitor status, n (%) | ||||||
| Never had inhibitors | 69 (93) | 32 (89) | 319 (88) | 26 (87) | 388 (89) | 58 (88) |
| Had inhibitors in the pastc | 5 (7) | 4 (11) | 42 (12) | 4 (13) | 47 (11) | 8 (12) |
| Treatment | ||||||
| Frequency of dose per week, mean (SD) | 2.9 (1.97) | 2.0 (0.52) | 3.0 (1.12) | 1.9 (0.98) | 3.0 (1.28) | 2.0 (0.73) |
| Factor per dose, mean (SD) (IU/kg) | 38.5 (13.9) | 49.5 (9.1) | 34.8 (14.7) | 53.0 (28.0) | 35.4 (14.6) | 50.8 (18.4) |
| Total dose per week, mean (SD) (IU/kg) | 106.2 (51.74) | 101.29 (37.97) | 102.8 (48.98) | 71.5 (25.29) | 103.3 (49.33) | 91.8 (36.93) |
EHL, extended half-life; SHL, standard half-life.
aTotal percentage may not equal 100% because of rounding.
bOther includes Native American, Afro-Caribbean, Asian-Indian subcontinent, Asian-other, Chinese, Middle Eastern, mixed race, and unknown.
cNo patient had inhibitors at baseline.